Understanding how disruptions in cellular machinery contribute to dementia.
Disruptions to nuclear proteostasis machinery as drivers of neurodegeneration in dementia.
This study is looking at how problems with protein management in brain cells might lead to Alzheimer's and similar diseases in people over 65, with the goal of finding new ways to help slow down or prevent these conditions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10973065 on NIH RePORTER |
What this research studies
This research investigates the role of nuclear proteostasis machinery in neurodegenerative diseases like Alzheimer's and frontotemporal lobar degeneration, particularly in individuals aged 65 and older. It aims to uncover how disruptions in cellular processes, such as protein aggregation and transport within neurons, contribute to the development of dementia. By studying these mechanisms, the research seeks to identify potential targets for therapeutic intervention that could slow or prevent neurodegeneration. The approach includes using model organisms to explore genetic factors and their impact on disease progression.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals aged 65 and older who are experiencing symptoms of dementia or are at risk for developing Alzheimer's disease.
Not a fit: Patients under the age of 65 or those without any signs of neurodegenerative diseases may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that slow the progression of dementia and improve the quality of life for affected individuals.
How similar studies have performed: Previous research has shown promising results in understanding the role of cellular mechanisms in neurodegeneration, suggesting that this approach could yield valuable insights.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Eck, Randall — University of Washington
- Study coordinator: Eck, Randall
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.